ParaPRO

What ParaPRO does

ParaPRO, LLC is a privately-held specialty pharmaceutical company headquartered in Carmel, Indiana, founded in 2002 under a licensing agreement with Eli Lilly to commercialize the naturally-derived anti-parasitic compound spinosad for human clinical uses. The company has built its business around a single asset class — topical spinosad formulations — with Natroba (spinosad) Topical Suspension 0.9% as the centerpiece product. Natroba received FDA approval in 2011 as a prescription treatment for head lice in patients six months of age and older, and is positioned against the documented 98.3% resistance of head lice to pyrethroid-based OTC products across 48 US states. The product targets the layer of the skin where lice reside (the stratum corneum) and is not systemically absorbed, allowing a 10-minute application time with a differentiated mechanism of action.

The company monetizes through branded prescription sales of Natroba and, more recently, an Authorized Generic (Spinosad Topical Suspension 0.9%) marketed via the SpinosadRx storefront. Go-to-market is an enterprise field-sales model: pharmaceutical representatives conduct 40-65 unique office visits per week targeting pediatricians, family physicians, NPs, PAs, and school nurses, supported by partnerships with NASN and AAFP. The product is reported as the most often prescribed Rx medication in the head lice category and is prescribed by an estimated three in five pediatricians. End consumers are families with school-aged children, with treatment failure (often after multiple OTC attempts) driving Rx conversion.

The R&D pipeline centers on extending spinosad into a second indication, with a Phase 3 randomized, double-blind, placebo-controlled study underway for scabies conducted in collaboration with Concentrics Research. ParaPRO is a family-controlled private company led by William Culpepper II (CEO) and William Culpepper III (President), with the proprietary spinosad intellectual property originating from Eli Lilly and earning a Presidential Green Chemistry Award from the EPA. The company operates exclusively in the United States, has no institutional investor or parent-company backing disclosed, and runs a focused product portfolio centered on anti-parasitic topical therapy.

Name

ParaPRO

Legal name

ParaPRO, LLC

Website

https://parapro.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Short description

ParaPRO is a private US specialty pharmaceutical company that develops and commercializes prescription topical spinosad treatments, primarily Natroba, an FDA-approved head-lice therapy sold to pediatricians, family physicians, and families across the United States.

Ownership category

akta.pro rank

Headquarters

HQ city

Carmel

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Personnel, Supply Chain, Technology or R&D, Operations

Revenue model

1. Prescription Pharmaceutical Sales: ParaPRO commercializes Natroba (spinosad) Topical Suspension 0.9% as an FDA-approved prescription medication for head lice. Revenue is generated through prescription sales to patients via pharmacies and healthcare providers, with the product being the most widely prescribed in its category.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

ParaPRO develops and commercializes prescription topical therapeutics for parasite infestations, with a portfolio centered on the spinosad compound. The lead product, Natroba (spinosad) Topical Suspension 0.9%, is an FDA-approved prescription treatment for head lice infestations in patients six months of age and older, and is the most often prescribed Rx medication in its category. The company also markets an Authorized Generic version (Spinosad Topical Suspension 0.9%) to broaden patient access, and is developing an investigational spinosad-based treatment for scabies.

Product overview

ParaPRO is a specialty pharmaceutical company offering a focused portfolio centered on spinosad-based topical treatments for parasitic infestations. The primary product is Natroba (spinosad) Topical Suspension 0.9%, an FDA-approved prescription medication for head lice in patients 6 months and older, which is the most widely prescribed in its category. The company also offers an Authorized Generic version (Spinosad Topical Suspension 0.9%) to improve patient access. Spinosad, the active compound, is a naturally occurring anti-parasitic agent derived from soil microorganisms that targets parasites in the stratum corneum without systemic absorption. The company is also developing investigational treatments for scabies.

Differentiator

Problem solved

Functional benefit

Brands

• Natroba: Natroba (spinosad) Topical Suspension, 0.9% - FDA-approved prescription treatment for head lice infestations in patients six months of age and older.
• Spinosad Topical Suspension, 0.9%

Products and services

• Natroba (spinosad) Topical Suspension, 0.9% FDA-approved prescription pediculicide for the topical treatment of head lice infestations in patients six months of age and older. Contains spinosad 0.9% as the active ingredient, applied for 10 minutes, and is the most often prescribed Rx medication in the head lice category.
• Spinosad Topical Suspension, 0.9% (Authorized Generic) Authorized generic version of Natroba marketed as Spinosad Topical Suspension 0.9% to broaden patient and family access to the spinosad-based head lice treatment.

Quantifiable outcome

• 98.3% resistance rate to pyrethroid and permethrin-based OTC treatments in 48 states
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Eli LillycoreOEM/ Whitelabel/ Licensing Partner · 1 January 2002ParaPRO was established in 2002 through an agreement with Eli Lilly to commercialize the spinosad compound for human clinical uses. This licensing agreement is the foundation of the company's business.
• National Association of School Nurses (NASN)coreStrategic or Co-development PartnerPartnership with NASN to support the broader professional community and bring about better outcomes for children and families affected by head lice infestations.
• American Academy of Family Physicians (AAFP)coreStrategic or Co-development PartnerPartnership with AAFP to bring about better outcomes for children and families and support the professional community with insights, tools, and resources.
• Concentrics ResearchminorImplementation/ SI/ Consulting PartnerConcentrics Research conducted ParaPRO's Phase 3, Randomized, Double Blind, Placebo-Controlled Study to assess the safety, efficacy and pharmacokinetics of the investigational product for the treatment of scabies.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Galderma: Large dermatology-focused pharmaceutical company with overlapping antiparasitic and topical franchises, serving the same prescriber base as ParaPRO but with a much broader portfolio across acne, rosacea, and skin health.
• Mission Pharmacal: Privately held specialty pharmaceutical company with comparable scale and family-ownership profile, operating in adjacent pediatric and women's health categories using a similar field-sales-driven Rx commercialization model.
• Aytu BioPharma: Specialty pharmaceutical company with a pediatric and rare disease focus that shares ParaPRO's commercial model of small, focused sales forces targeting prescribers in niche indications.
• Padagis: Specialty and generic topical pharmaceutical company with deep expertise in skin-directed Rx products, providing a comparable benchmark for niche topical Rx commercialization and authorized generic strategies.
• Mayne Pharma: Specialty and generic pharmaceutical company with relevant dermatology and women's health Rx portfolios, providing a comparable size and business model benchmark for niche Rx commercialization in the US.

Direct peers

• Azurity Pharmaceuticals: Specialty pharma that markets Rx head lice treatments including Sklice (ivermectin 0.5%), directly competing with Natroba for the same pediatric and family practice prescribers and patient population.
• Verrica Pharmaceuticals: Niche specialty pharmaceutical company with a focused portfolio of FDA-approved topical prescription therapies (e.g., Ycanth) for skin conditions, sharing ParaPRO's model of a small commercial organization targeting prescribers in a single dermatologic/parasitic indication.

Others

• Bayer Consumer Health: Bayer's Rid brand is a leading OTC head lice treatment, representing the OTC competitive front that ParaPRO's Rx alternative must reach via pediatrician and family practice referrals after multiple OTC failures.
• Church & Dwight: Consumer health company whose Nix brand is the leading OTC head lice treatment in the US, representing the OTC-first competitive dynamic that ultimately funnels treatment-failure patients toward Rx options like Natroba.

Emerging players

• Arcutis Biotherapeutics: Emerging dermatology specialty pharmaceutical company with a focused portfolio of topical prescription therapies (e.g., Zoryve), sharing ParaPRO's lean commercial approach to single-indication dermatologic categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/parapropharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ParaPRO